Add this topic to your myFT Digest for news straight to your inbox
Pharma follows banking in post financial crisis change
Former big investor in drugmaker alleges executives wiped out billions in shareholder value
Sales trends, not legal investigations, are the key
Drugmaker seeks to reassure investors it can cope with $31bn debt pile
Michael Pearson insists he remains confident of drugmaker’s prospects despite stock sale
Fidelity pulls out of Dimon governance push; Jérôme Kerviel, Valeant, Suzuki and Time Out featured
New chief executive will consider pulling the plug on unprofitable agreement within months
Drugmaker’s shares plunge as it misses lowered profit forecasts
As forecasts keep falling, so does the pharma company’s credibility
McKinsey quietly runs an investment arm for partners but experts warn of conflicts of interest
Valeant, Barclays, Alliance Trust, Zurich Insurance and LSE-Deutsche Börse featured
Drugmaker’s shares fell nearly 90% during Michael Pearson’s watch
Japanese drugmaker and private equity firm reported to have made offer
Bill Doyle leaves Pershing Square as fund seeks to recover from pharmaceuticals fallout
Drugmaker staves off default on $30bn and overhauls board
Hedge fund billionaire in mea culpa as drug prices put under pressure
Similar stories with a crucial difference
Directors look to industry veteran to stabilise scandal-hit drugmaker
International Edition